Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

A miracle drug just wiped out WeightWatchers International’s (WW) 60-year empire. Here’s how Ozempic disrupted the weight ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Over the course of 12 weeks, participants taking the highest dose of amycretin (2 x 50 mg) lost an average of 13.1% of their body weight. Those on a smaller dose (50 mg) lost about 10.4%. In ...

Furthermore, Novo Nordisk is currently in the early stages ... Finally, the regulatory process for Amycretin is ongoing, with an FDA decision expected in the coming months. The company anticipates ...